Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) Net Margin (2016 - 2025)

Historic Net Margin for Seres Therapeutics (MCRB) over the last 8 years, with Q4 2023 value amounting to 10204.69%.

  • Seres Therapeutics' Net Margin fell 31486900.0% to 10204.69% in Q4 2023 from the same period last year, while for Sep 2025 it was 9311.11%, marking a year-over-year decrease of 848717000.0%. This contributed to the annual value of 60.48% for FY2023, which is 35699800.0% up from last year.
  • As of Q4 2023, Seres Therapeutics' Net Margin stood at 10204.69%, which was down 31486900.0% from 2206.13% recorded in Q3 2023.
  • Over the past 5 years, Seres Therapeutics' Net Margin peaked at 53.83% during Q3 2021, and registered a low of 13634.87% during Q1 2023.
  • Moreover, its 5-year median value for Net Margin was 652.76% (2021), whereas its average is 2492.78%.
  • Data for Seres Therapeutics' Net Margin shows a peak YoY increase of 53604100bps (in 2023) and a maximum YoY decrease of -98422300bps (in 2023) over the last 5 years.
  • Over the past 5 years, Seres Therapeutics' Net Margin (Quarter) stood at 248.01% in 2019, then skyrocketed by 59bps to 102.73% in 2020, then crashed by -574bps to 692.44% in 2021, then crashed by -919bps to 7056.0% in 2022, then plummeted by -45bps to 10204.69% in 2023.
  • Its last three reported values are 10204.69% in Q4 2023, 2206.13% for Q3 2023, and 36.81% during Q2 2023.